PUBLIC COMPANY
save$ORKAOruka Therapeutics, Inc.
$ORKA84.52+1.32%Menlo Park, CA, USupdated 23h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
- phase2ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
- phase2Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
- phase2ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
- phase2Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
- phase1ORKA-001 in Healthy Volunteers
- phase1ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (4)
- Apr 15, 26option exerciseGoncalves Joana · Chief Medical Officer3,500 sh
- Apr 15, 26option exerciseGoncalves Joana · Chief Medical Officer3,500 sh
- Apr 15, 26option exerciseGoncalves Joana · Chief Medical Officer3,500 sh
- Apr 15, 26option exerciseGoncalves Joana · Chief Medical Officer3,500 sh
🐶 Hiring Signal
News
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 6d ago
- Oruka surges as long-acting psoriasis drug shows early promiseA therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.biopharma_dive · 5mo ago
- STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage studyA long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical trial, its maker, Oruka Therapeutics, reported.stat · 5mo ago
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that